Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields; Brian A. Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G. Press; Barry N. Kreiswirth; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1093/cid/ciw636

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields
, Brian A. Potoski
, Ghady Haidar
, Binghua Hao
, Yohei Doi
, Liang Chen
, Ellen G. Press
, Barry N. Kreiswirth
, Cornelius J. Clancy
, M. Hong Nguyen

Center for Discovery and Innovation

University of Pittsburgh
Rutgers - The State University of New Jersey, Newark
VA Medical Center

Research output: Contribution to journal › Article › peer-review

409 Scopus citations

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Original language	English
Pages (from-to)	1615-1618
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	63
Issue number	12
DOIs	https://doi.org/10.1093/cid/ciw636
State	Published - 15 Dec 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

carbapenem-resistant Enterobacteriaceae
ceftazidime-avibactam resistance
Klebsiella pneumoniae carbapenemase

Access to Document

10.1093/cid/ciw636

Cite this

Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016). Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 63(12), 1615-1618. https://doi.org/10.1093/cid/ciw636

@article{1af08f02f2934268ba5d1614b047a4cf,

title = "Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections",

abstract = "Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59\% (22/37) and 76\% (28/37), respectively. In 23\% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27\% (10/37). Ceftazidime-avibactam resistance was detected in 30\% (3/10) of microbiologic failures.",

keywords = "carbapenem-resistant Enterobacteriaceae, ceftazidime-avibactam resistance, Klebsiella pneumoniae carbapenemase",

author = "Shields, \{Ryan K.\} and Potoski, \{Brian A.\} and Ghady Haidar and Binghua Hao and Yohei Doi and Liang Chen and Press, \{Ellen G.\} and Kreiswirth, \{Barry N.\} and Clancy, \{Cornelius J.\} and Nguyen, \{M. Hong\}",

year = "2016",

month = dec,

day = "15",

doi = "10.1093/cid/ciw636",

language = "English",

volume = "63",

pages = "1615--1618",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "12",

}

Shields, RK, Potoski, BA, Haidar, G, Hao, B, Doi, Y, Chen, L, Press, EG, Kreiswirth, BN, Clancy, CJ & Nguyen, MH 2016, 'Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections', Clinical Infectious Diseases, vol. 63, no. 12, pp. 1615-1618. https://doi.org/10.1093/cid/ciw636

TY - JOUR

T1 - Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

AU - Shields, Ryan K.

AU - Potoski, Brian A.

AU - Haidar, Ghady

AU - Hao, Binghua

AU - Doi, Yohei

AU - Chen, Liang

AU - Press, Ellen G.

AU - Kreiswirth, Barry N.

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

AB - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

KW - carbapenem-resistant Enterobacteriaceae

KW - ceftazidime-avibactam resistance

KW - Klebsiella pneumoniae carbapenemase

UR - https://www.scopus.com/pages/publications/84995524184

U2 - 10.1093/cid/ciw636

DO - 10.1093/cid/ciw636

M3 - Article

C2 - 27624958

AN - SCOPUS:84995524184

SN - 1058-4838

VL - 63

SP - 1615

EP - 1618

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 12

ER -

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this